Surrozen to Present at Upcoming Healthcare Investor Conference TMCnet News [November 06, 2026] | / | Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) - Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim's 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 Fireside Chat at 1:30 PM Pacific Time / 4:30 PM Eastern Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcast will be archived on the website at www.surrozen.com for at least 30 days. About Surrozen Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Its approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are ccompanied by words such as "will," "plan," "intend," "potential," "expect," "could," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen's cash runway into 2029 (including completion of the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b clinical development of SZN-8143) and Surrozen's discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, such as the Company's plan to dose the first patient in the DUET Phase 1b/2a study in DME patients in the fourth quarter of 2026, the availability of data, such as initial data from the DUET study being anticipated in the second half of 2027, Surrozen's plan to develop SZN-8141 in neovascular age-related macular degeneration, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates, and the anticipated use of proceeds from the second closing of the private placement). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company's ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen's ability to identify, develop and commercialize drug candidates; Surrozen's ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen's Annual Report on Form 10-K for the year ended December 31, 2025, and Surrozen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the Securities and Exchange Commission ("SEC") under the heading "Risk Factors," and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or its assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen's expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Investor/Media Contact Email: [email protected] [ Back To TMCnet.com's Homepage] |

Surrozen, a biotechnology company developing Wnt-based eye therapies, has closed the second and final tranche of its March 2025 private placement, raising about $95.1 million in gross proceeds before fees and expenses. The closing followed US Food and Drug Administration clearance on October 2, 2026, of the company's Investigational New Drug application for SZN-8141, which triggered the second tranche. Surrozen expects the cash to fund operations into 2029. That covers the Phase 1b/2a DUET study of SZN-8141 in diabetic macular edema and early development of SZN-8143. First patient dosing is expected in the fourth quarter of 2026, with initial data in the second half of 2027. The Series E warrants carry an exercise price of $11.54 per share.

Surrozen sees unusually large options volume (NASDAQ:SRZN). October 12, 2026 Key points. * Unusual options activity: Traders purchased 4,277 Surrozen call options, approximately 233% above the average volume of 1,283 contracts. * Analyst sentiment is moderately bullish: Surrozen has an average "Moderate Buy" rating and a consensus price target of $48.33, despite ratings ranging from "Strong Buy" to "Sell." * Shares declined while quarterly results exceeded expectations: The stock fell $5 to $24.69, while Surrozen reported a quarterly loss of $0.41 per share versus the $1.29 expected loss and revenue of $5 million versus estimates of $0.47 million. * Five stocks we like better than Surrozen. Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock traders acquired 4,277 call options on the stock. This represents an increase of approximately 233% compared to the average volume of 1,283 call options. Analyst ratings changes. Several equities research analysts recently commented on SRZN shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Surrozen in a research note on Friday, July 17th. William Blair initiated coverage on shares of Surrozen in a report on Thursday, August 20th. They set an "outperform" rating and a $51.00 price target on the stock. Zacks Research upgraded shares of Surrozen from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $54.00 price objective (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $48.33. Surrozen stock performance. Shares of NASDAQ SRZN traded down $5.00 during mid-day trading on Monday, reaching $24.69. 759,382 shares of the company traded hands, compared to its average volume of 244,543. The company's fifty day moving average is $23.54 and its two-hundred day moving average is $25.12. Surrozen has a fifty-two week low of $11.39 and a fifty-two week high of $37.83. The stock has a market cap of $286.64 million, a PE ratio of -0.61 and a beta of 0.47. Surrozen (NASDAQ:SRZN - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.88. The company had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.47 million. Research analysts forecast that Surrozen will post -1.01 earnings per share for the current year. Insider activity at Surrozen. In related news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the completion of the sale, the insider directly owned 574,047 shares in the company, valued at approximately $12,198,498.75. This trade represents a 36.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 31.74% of the stock is currently owned by corporate insiders. Institutional inflows and outflows. Several institutional investors have recently bought and sold shares of the company. Spruce Street Capital LP bought a new stake in Surrozen during the fourth quarter valued at about $9,764,000. 5AM Venture Management LLC grew its position in shares of Surrozen by 25.0% in the fourth quarter. 5AM Venture Management LLC now owns 387,500 shares of the company's stock valued at $8,758,000 after purchasing an additional 77,500 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Surrozen in the first quarter valued at about $6,682,000. Eversept Partners LP increased its stake in shares of Surrozen by 23.8% in the fourth quarter. Eversept Partners LP now owns 95,286 shares of the company's stock worth $2,153,000 after purchasing an additional 18,289 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Surrozen by 117.1% during the 1st quarter. Renaissance Technologies LLC now owns 49,126 shares of the company's stock worth $1,431,000 after purchasing an additional 26,500 shares during the last quarter. Institutional investors own 66.57% of the company's stock. About Surrozen. Surrozen, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively activate the Wnt signaling pathway, which plays an important role in tissue repair, regeneration and maintenance. The company uses proprietary antibody-based technologies designed to stimulate Wnt signaling in specific tissues while limiting potential effects elsewhere in the body. Discover more MarketBeat Pro subscription MarketBeat All Access Stock research tools Surrozen's pipeline has included SZN-1326, an investigational Wnt pathway activator being developed for inflammatory bowel diseases such as ulcerative colitis, and SZN-413, an investigational therapy targeting the FZD4 Wnt signaling pathway for retinal vascular diseases. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Surrozen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surrozen wasn't on the list. While Surrozen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Continue following MarketBeat